等待开盘 12-17 09:30:00 美东时间
0.000
0.00%
PureTech Health ( ($GB:PRTC) ) has provided an announcement. PureTech Health an...
12-11 01:48
LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a potentially
12-06 02:02
LYT-200 continues to demonstrate strong evidence of clinical activity, survival benefit and a highly favorable safety profile in heavily pretreated relapsed/refractory AML patients, both as a monotherapy and in
11-03 22:18
Patients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of lung function with favorable tolerabilityFindings further substantiate safety and efficacy
09-29 15:20
U.S. stocks were higher, with the Nasdaq Composite gaining more than 100 points...
09-19 22:31
PureTech Health ( ($GB:PRTC) ) just unveiled an announcement. Seaport Therapeut...
09-11 19:07
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据PureTech (PRTC)业绩会实录,我总结以下财务业绩回顾:</p> <p>• 财务业绩: - 截至2025年第二季度末,公司持有现金、现金等价物和短期投资约3.2亿美元 - 2025年上半年合并运营支出约5000万美元 - 2025年上半年现金消耗约4600万美元</p> <p>• 财务指标变化: - 2025年上半年合并运营支出同比下降,从2024年上半年的6670万美元降至约5000万美元,降幅约25% - 截至2025年第二季度末的现金、现金等价物和短期投资余额较2024年末的3.67亿美元减少约13% -
09-03 12:05
PureTech Health plc press release (OTC:PTCHF): 1H ~$320M PureTech level cash, cash equivalents and short-term investments as of June 30, 2025. More on PureTech PureTech Health announces CEO transition...
08-28 16:33
Companies Reporting Before The Bell • Li Auto (NASDAQ:LI) is expected to report...
08-28 16:32
PureTech Health (NASDAQ:PRTC) reported quarterly losses of $(0.19) per share. This is a 26.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported $1.85 million in sales
08-28 14:37